Progression-seeking bias and rational optimism in research and development

Nature Reviews Drug Discovery

Volumn 14, Issue 3, 2015, Pages 219-221

  Lendrem, Dennis W ^a   Lendrem, B Clare ^a   Peck, Richard W ^b   Senn, Stephen C ^c   Day, Simon ^d   Isaacs, John D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d Clinical Trials Consulting Training Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ACCESS TO INFORMATION; DECISION MAKING; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; INFORMATION SEEKING; LETTER; OPTIMISM; PRIORITY JOURNAL; PROBABILITY; PROCESS DEVELOPMENT; ANIMAL; DRUG DESIGN; ECONOMICS; HUMAN; LABORATORY DIAGNOSIS; MEDICAL RESEARCH; PHARMACOLOGY; STATISTICS AND NUMERICAL DATA; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; DRUG DESIGN; DRUG INDUSTRY; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; PHARMACOLOGY;

EID: 84924094925     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4320-c1     Document Type: Letter

References (13)

1. Schulze, U. et al. R&D productivity: on the comeback trail. Nature Rev. Drug Discov. 13, 331-332 (2014).
2. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
3. Garnier, J. Rebuilding the R.&D engine in big pharma. Harvard Bus. Rev. 86, 68-76 (2008).
4. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203-214 (2010).
5. Peck, R. W. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. Drug Discov. Today. 12, 289-294 (2007).
6. Kahneman, D. Thinking, Fast and Slow. (Macmillan, 2011).
7. Arkes, H. & Ayton, P. The sunk cost and Concorde effects: are humans less rational than lower animals? Psychol. Bull. 125, 591-600 (1998).
8. Kahneman, D. & Lovallo, D. Timid choices and bold forecasts: a cognitive perspective on risk-taking. Manage. Sci. 39, 17-31 (1993).
9. Cook, D. et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nature Rev. Drug Discov. 13, 419-431 (2014).
10. Arrowsmith, J. & Miller, P. Trial Watch: Phase II and Phase III attrition rates 2011-2012. Nature Rev. Drug Discov. 12, 569 (2013).
11. Sokol-Hessner, P. et al. Thinking like a trader selectively reduces individuals' loss aversion. Proc. Natl Acad. Sci. USA 106, 5035-5040 (2009).
12. Lovallo, D. & Kahneman, D. Delusions of success: how optimism undermines executives' decisions. Harvard Bus. Rev. 81, 56-63 (2003).
13. Dimitri, N. An assessment of R&D productivity in the pharmaceutical industry. Trends Pharmacol. Sci. 32, 683-685 (2011).